Perinephric invasion as a prognostic factor in non-metastatic renal cell carcinoma: analysis of a nation-wide registry program.


Journal

Japanese journal of clinical oncology
ISSN: 1465-3621
Titre abrégé: Jpn J Clin Oncol
Pays: England
ID NLM: 0313225

Informations de publication

Date de publication:
01 Aug 2019
Historique:
received: 01 01 2019
revised: 16 03 2019
accepted: 05 04 2019
pubmed: 13 4 2019
medline: 9 1 2020
entrez: 13 4 2019
Statut: ppublish

Résumé

Perinephric fat invasion (PFI) of renal cell carcinoma (RCC) is known to be associated with adverse pathological features and poor prognosis. We analyzed these associations using a sub-group of the RCC registry of The Cancer Registration Committee of the Japanese Urological Association. The study cohort of 2998 non-metastatic cases was retrieved from RCC registry (3648 in total). We compared clinicopathological characteristics of cases with PFI (n = 256) and without PFI (n = 2742), and investigated the impact of PFI on cancer-specific survival using univariate and multivariate analyses. Compared with non-PFI cases, PFI cases were older (P = 0.003), and more likely to be hypertensive (P = 0.034) and symptomatic at presentation (P < 0.001). PFI tumors were larger (P < 0.001), and more often have sarcomatoid component (P < 0.001) and tumor thrombus (P < 0.001). Cancer-specific survival was significantly shorter in cases with PFI than without (P < 0.001). The difference in survival tended to be greater in cases with large tumors but was significant in small tumor sub-groups. Cancer-specific survival was significantly shorter in cases with both PFI and renal vein involvement (RVI) in comparison to those with PFI or RVI alone (P = 0.011, P = 0.007, respectively). On multivariate analysis PFI with and without sinus fat invasion remained as an independent risk factor along with symptom at presentation, low body mass index, hypertension, multiple tumors, large tumor size (>7.0 cm), sarcomatoid component and RVI. PFI was associated with advanced age and aggressive pathological features. PFI is an independent prognostic factor in non-metastatic RCC.

Identifiants

pubmed: 30977820
pii: 5448906
doi: 10.1093/jjco/hyz054
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

772-779

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Haruki Kume (H)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Department of Urology, National Center for Global Health and Medicine, Tokyo, Japan.

Yukio Homma (Y)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.

Nobuo Shinohara (N)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Renal and Genitourinary Surgery, Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

Wataru Obara (W)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Iwate Medical University, Morioka, Japan.

Tsunenori Kondo (T)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Tokyo Women's Medical University, Tokyo, Japan.

Go Kimura (G)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Nippon Medical School, Tokyo, Japan.

Hiroyuki Fujimoto (H)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Urology Division, National Cancer Center Japan, Tokyo, Japan.

Norio Nonomura (N)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Graduate School of Medicine, Osaka University, Osaka, Japan.

Fumiya Hongo (F)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Graduate School of Medical Sciences, Kyoto Prefectural University of Medicine, Kyoto, Japan.

Takayuki Sugiyama (T)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Hamamatsu University School of Medicine, Shizuoka, Japan.

Masayuki Takahashi (M)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.

Hiro-Omi Kanayama (HO)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.

Tomoharu Fukumori (T)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Institute of Biomedical Sciences, Tokushima University Graduate School.

Masatoshi Eto (M)

The Cancer Registration Committee of the Japanese Urological Association, Japan.
Department of Urology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH